EP01: Closing the Cancer Care Gap with the Power of Precision Oncology
According to the American Cancer Society, cancer is responsible for approximately one-sixth of deaths worldwide, surpassing the combined toll of AIDS, tuberculosis, and malaria. It ranks as the first or second leading cause of mortality in the majority of countries.
The evolution of genomic technologies has played a pivotal role in identifying and understanding the factors that cause cancer, paving the way for precision medicine in oncology.
In this episode, we delve into the work of Dr. Marie-Laure Yaspo at ALACRIS Theranostics. Dr. Yaspo and her team are at the forefront of bridging the gap in cancer care, employing evidence-based approaches across the spectrum of cancer management, from prevention to treatment. This effort is supported by the advanced life science technologies provided by MGI.
MGI Podcast EP01: Closing the Cancer Care Gap with the Power of Precision Oncology
Dr. Marie-Laure Yaspo undertook her postdoctoral research at the Imperial Cancer Research Fund in London, UK. Since 1996, she has led a research group at the Max Planck Institute for Molecular Genetics (MPIMG) in Berlin. Dr. Yaspo is the Founder and CEO of Alacris Theranostics GmbH.
Presently, she serves as the head of the Otto Warburg Laboratory, focusing on "Gene Regulation and Systems Biology of Cancer" at MPIMG. Dr. Yaspo has played a pivotal role in coordinating the International Consortium for the mapping and sequencing of Human chromosome 21, contributing significantly to the Human Genome Project.
Watch EP02 "Rare Disease Mendelian Disorders & Sequencing Breakthroughs" Now
About Alacris Theranostics GmbH
Founded in 2008, Alacris Theranostics GmbH is headquartered in Berlin and was established by trailblazers in technology development, genomics, next-generation sequencing applications, and systems biology.
Since 2000, the company has been dedicated to evolving its core technologies with the goal of transforming research breakthroughs into tangible advantages for both patients and society. This commitment supports the advancement of innovative strategies in precision medicine.
About MGI
MGI Tech Co., Ltd. (referred to as MGI) is committed to building core tools and technology to lead life science through intelligent innovation. MGI focuses on R&D, production, and sales of DNA sequencing instruments, reagents, and related products to support life science research, agriculture, precision medicine, and healthcare. MGI is a leading producer of clinical high-throughput gene sequencers, and its multi-omics platforms include genetic sequencing, mass spectrometry, medical imaging, and laboratory automation.
Founded in 2016, MGI has more than 2,900 employees, nearly half of whom are R&D personnel. MGI operates in 100 countries and regions and has established multiple research and production bases around the world. Providing real-time, comprehensive, life-long solutions, its vision is to enable effective and affordable healthcare solutions for all.
